MedPath

HARMONIE Trial Reimagines Commercial Clinical Trial Design with Nirsevimab

• The HARMONIE trial investigated the impact of nirsevimab on hospitalizations related to respiratory syncytial virus (RSV) in infants. • Conducted across France, Germany, and the UK, the trial adopted a pragmatic approach to assess nirsevimab's effectiveness. • Professor Saul Faust will present the trial's innovative design and execution at an upcoming PCT Grand Rounds session. • The study aims to provide insights into optimizing the design and delivery of commercial clinical trials.

Professor Saul Faust of the University of Southampton is set to present "The HARMONIE Trial: Reimagining How to Design and Deliver Contract Commercial Clinical Trials" at the PCT Grand Rounds on September 13, 2024. The HARMONIE trial, a pragmatic study conducted in France, Germany, and the United Kingdom, examined the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)-associated lower respiratory tract infection in healthy infants.
Faust, a professor of pediatric immunology and infectious diseases, leads the National Institute for Health Research (NIHR) Southampton Clinical Research Facility and serves as the clinical director of the Wessex Local Clinical Research Network. His presentation will delve into the innovative strategies employed in the HARMONIE trial to optimize the design and execution of commercial clinical trials.
The HARMONIE trial's pragmatic design allowed for real-world assessment of nirsevimab's effectiveness in preventing RSV-related hospitalizations, offering valuable insights for future clinical trial methodologies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

SUO 2024: Update on Neoadjuvant Therapy Trials in RCC

At the 2024 Society of Urologic Oncology annual meeting, Dr. Naomi Haas provided an update on neoadjuvant therapy trials for renal cell carcinoma (RCC), highlighting the safety and limited efficacy of current treatments, ongoing trials, and the potential of biomarkers like KIM-1 for future research.

UK and Switzerland Partner to Fund Clinical Trials Addressing Unmet Medical Needs

The NIHR and SNSF are partnering to provide £8 million in funding for joint Swiss-UK clinical trials focused on areas of unmet need.
The funding aims to support clinical studies evaluating the efficacy and cost-effectiveness of interventions for diagnosing, preventing, or treating diseases.

LungSMART Trial Aims to Boost Lung Cancer Screening via Telehealth in Community Health Centers

LungSMART, supported by the NCI, joins the NIH Pragmatic Trials Collaboratory to improve lung cancer screening rates.
The trial will implement telehealth interventions in Utah community health centers to overcome logistical barriers and hesitancy.

SynAct Pharma's Resomelagon Receives EU Trial Approval for Phase 2b Rheumatoid Arthritis Study

SynAct Pharma received EU approval for its Phase 2b ADVANCE study of resomelagon (AP1189) in newly diagnosed severe rheumatoid arthritis (RA) patients.
The ADVANCE study will evaluate three doses of resomelagon versus placebo, in combination with methotrexate, as a first-line RA treatment.

Digital Coaching Service Shows Promise in Managing Hypertension and Depression Comorbidity

A randomized control trial in Northumbria assesses the feasibility of using Holly Health's digital coaching service for patients with hypertension and depression/anxiety.
After 12 weeks, 64% of patients found the service useful, and 69% reported benefiting from it, with 92% finding it acceptable as a digital health intervention.

Bausch Health's RED-C Trials Evaluate Rifaximin Formulation for Hepatic Encephalopathy Prevention

Bausch Health's RED-C program investigates a novel rifaximin formulation (SSD-40IR) for delaying the onset of first overt hepatic encephalopathy (OHE) hospitalization in cirrhosis patients.
The Phase 3 trials are randomized, double-blind, and placebo-controlled, enrolling adults with cirrhosis and medically controlled ascites but no prior OHE history.

Resonance Health Secures $13.8 Million Agreement with Sun Pharmaceutical for Clinical Trial Services

Resonance Health has secured a $13.8 million agreement with Sun Pharmaceutical to serve as the local Australian sponsor for a global clinical trial.
The agreement spans 24 months and includes clinical research organization, trial site, and imaging analysis services for Sun Pharmaceutical's new drug compound.

NIH Collaboratory Adds APA-SM Trial to Evaluate Acupressure for Chronic Pain Management

The NIH Pragmatic Trials Collaboratory welcomes the APA-SM trial, focusing on personalized auricular point acupressure for chronic pain self-management in rural areas.
The APA-SM trial will conduct a pragmatic study of a 4-week auricular point acupressure intervention in rural Texas and South Carolina.

Synergia Medical's NAO.VNS System Successfully Implanted in First-in-Human Epilepsy Study

Synergia Medical successfully implanted its NAO.VNS system in two patients with drug-resistant epilepsy as part of the AURORA study.
The first-in-human implantations occurred at Cliniques Universitaires Saint-Luc and UZ Gent, with both patients recovering fully and starting stimulation therapy.

Mindfulness Training Shows Promise in Managing Chronic Pain: LAMP Trial Results

The LAMP pragmatic clinical trial evaluated the effectiveness of mindfulness training for chronic pain management.
The study compared two different approaches to mindfulness training in a multisite trial.

Reference News

[1]
September 11, 2024: HARMONIE and a New Approach to Commercial Clinical Trials, in ...
rethinkingclinicaltrials.org · Sep 11, 2024

Saul Faust presents 'The HARMONIE Trial: Reimagining How to Design and Deliver Contract Commercial Clinical Trials' on S...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy